Cara Therapeutics Revenue and Competitors
Estimated Revenue & Valuation
- Cara Therapeutics's estimated annual revenue is currently $29.4M per year.
- Cara Therapeutics's estimated revenue per employee is $288,529
- Cara Therapeutics's total funding is $472.4M.
Employee Data
- Cara Therapeutics has 102 Employees.
- Cara Therapeutics grew their employee count by 0% last year.
Cara Therapeutics's People
| Name | Title | Email/Phone |
|---|---|---|
1 | CFO | Reveal Email/Phone |
2 | Sr VP Regulatory Affairs and Quality Assurance | Reveal Email/Phone |
3 | Sr. VP, Commercial Operations | Reveal Email/Phone |
4 | VP | Reveal Email/Phone |
5 | VP Research & Development | Reveal Email/Phone |
6 | VP, Head Accounting and Controller | Reveal Email/Phone |
7 | Head Biometrics | Reveal Email/Phone |
8 | VP, Research And Development | Reveal Email/Phone |
9 | VP, Quality Assurance | Reveal Email/Phone |
10 | General Counsel, Secretary and Chief Compliance Officer | Reveal Email/Phone |
Cara Therapeutics Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $139.1M | 412 | 0% | N/A | N/A |
#2 | $7.1M | 33 | -40% | N/A | N/A |
#3 | $47.6M | 164 | 20% | $20M | N/A |
#4 | $30.8M | 114 | -6% | $15.6M | N/A |
#5 | $10.1M | 49 | 0% | $37M | N/A |
#6 | $37.3M | 138 | -3% | N/A | N/A |
#7 | $161.5M | 471 | 7% | $156.1M | N/A |
#8 | $0.7M | 12 | -37% | $8.2M | N/A |
#9 | $63M | 244 | -6% | $385M | N/A |
#10 | $10.1M | 49 | 0% | $175.5M | N/A |
What Is Cara Therapeutics?
Cara Therapeutics is an emerging biotechnology company focused on developing novel therapeutics to treat pain, inflammation and pruritus. Cara possesses both near-term clinical development opportunities combined with proprietary approaches to developing first-in-class novel therapeutics. Cara's most advanced patented compound, CR845, is currently undergoing clinical testing for acute pain and uremic pruritus. This compound possesses analgesic, anti-inflammatory and antipruritic activities appropriate for multiple therapeutic applications. In addition, Cara aims to develop a future pipeline of first-in-class molecules at novel analgesic and anti-inflammatory targets using its proprietary drug screening technology.
keywords:N/A
$472.4M
Total Funding
102
Number of Employees
$29.4M
Revenue (est)
0%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Cara Therapeutics News
Cara Therapeutics Inc (CARA) is near the top in its sector according to InvestorsObserver. CARA gets an overall rating of 15.
Cara Therapeutics is an early commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients...
Cara Therapeutics is an early commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients...
Cara Therapeutics tried to misdirect investors away from the failure of its osteoarthritis pain pill by burying negative results from a mid-stage clinical trial in the middle of a press release issued Thursday night. The ploy didn’t work. Cara shares plunged, with the stock trading down 30 perce ...
Cara Therapeutics, Inc., a Shelton, CT-based biotechnology company focused on developing novel therapeutics to treat pain and inflammation associated with diverse medical conditions, closed on a $15m Series D financing. The round was led by new investor, Rho Ventures, with participation from ex ...
Other Companies in Stamford
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $25.6M | 102 | 24% | N/A |
#2 | $23.2M | 102 | -14% | N/A |
#3 | $25.6M | 102 | 62% | N/A |
#4 | $12.4M | 103 | 26% | N/A |
#5 | $18.7M | 104 | 25% | N/A |